Centre for Advanced Research in Environmental Genomics, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Adv Clin Chem. 2012;57:99-138. doi: 10.1016/b978-0-12-394384-2.00004-8.
Mitochondria are ubiquitous organelles in eukaryotic cells principally responsible for regulating cellular energy metabolism, free radical production, and the execution of apoptotic pathways. Abnormal oxidative phosphorylation (OXPHOS) and aerobic metabolism as a result of mitochondrial dysfunction have long been hypothesized to be involved in tumorigenesis. In the past decades, numerous somatic mutations in both the coding and control regions of mitochondrial DNA (mtDNA) have been extensively examined in a broad range of primary human cancers, underscoring that accumulation of mtDNA alterations may be a critical factor in eliciting persistent mitochondrial defects and consequently contributing to cancer initiation and progression. However, the roles of these mtDNA mutations in the carcinogenic process remain largely unknown. This review outlines a wide variety of somatic mtDNA mutations identified in common human malignancies and highlights recent advances in understanding the causal roles of mtDNA variations in neoplastic transformation and tumor progression. In addition, it briefly illustrates how mtDNA alterations activate mitochondria-to-nucleus retrograde signaling so as to modulate the expression of relevant nuclear genes or induce epigenetic changes and promote malignant phenotypes in cancer cells. The present state of our knowledge regarding how mutational changes in the mitochondrial genome could be used as a diagnostic biomarker for early detection of cancer and as a potential target in the development of new therapeutic approaches is also discussed. These findings strongly indicate that mtDNA mutations exert a crucial role in the pathogenic mechanisms of tumor development, but continued investigations are definitely required to further elucidate the functional significance of specific mtDNA mutations in the etiology of human cancers.
线粒体是真核细胞中普遍存在的细胞器,主要负责调节细胞能量代谢、自由基产生和细胞凋亡途径的执行。由于线粒体功能障碍导致的异常氧化磷酸化(OXPHOS)和有氧代谢长期以来一直被认为与肿瘤发生有关。在过去的几十年中,人们广泛研究了多种原发性人类癌症中线粒体 DNA(mtDNA)的编码和调控区的体细胞突变,这强调了 mtDNA 改变的积累可能是引发持续线粒体缺陷的关键因素,并进而有助于癌症的起始和进展。然而,这些 mtDNA 突变在致癌过程中的作用在很大程度上仍然未知。本综述概述了常见人类恶性肿瘤中鉴定出的多种体细胞 mtDNA 突变,并强调了最近在理解 mtDNA 变异在肿瘤转化和肿瘤进展中的因果作用方面的进展。此外,本文还简要说明了 mtDNA 改变如何激活线粒体-核逆行信号,从而调节相关核基因的表达或诱导表观遗传变化,并促进癌细胞的恶性表型。还讨论了线粒体基因组突变作为癌症早期检测的诊断生物标志物以及作为开发新治疗方法的潜在靶点的应用的当前知识状态。这些发现强烈表明,mtDNA 突变在肿瘤发展的发病机制中发挥着关键作用,但需要进一步的研究来阐明特定 mtDNA 突变在人类癌症病因学中的功能意义。